Back

Phenotypic characterization of pulmonary hypertension associated with left heart disease in contemporary practice: insights from the Re‑PHIRE Trial

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension associated with left heart disease Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)

6 More presentations in this session

Presentation thumbnail
Diagnosing post-capillary pulmonary hypertension in the era of mild pulmonary hypertension: what is the optimal threshold of resting pulmonary arterial wedge pressure?
Doctor S. Taya (Okayama, JP)
Abstract Slides
Presentation thumbnail
Post-capillary pulmonary hypertension: impact of the current ESC/ERS updated PVR cutoff on pulmonary vascular disease and RV arterial coupling
Professor J. Grignola Rial (Montevideo, UY)
Presentation thumbnail
Right heart dimensions and pulmonary arterial wedge pressure in pulmonary arterial hypertension: exploring a controversial relationship
Assistant Professor S. Papa (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Viscosity-corrected pulmonary vascular resistance: a prognostic marker in left ventricular assist device candidates
Doctor B. Lakatos (Budapest, HU)
Abstract Slides
Presentation thumbnail
Deep phenotyping of the right ventricular–pulmonary circulation reveals biological overlap between pulmonary arterial hypertension and combined post-capillary pulmonary hypertension
Doctor J. Rodriguez Arias (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Pulmonary hypertension associated with left heart disease

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Prevalence and predictors of pulmonary vascular disease in patients with advanced heart failure with reduced ejection fraction
22 May 2023
thumbnail
Congress Presentation
Pulmonary hypertension associated with left heart disease: prevalence, phenotyping, and management
29 August 2026
thumbnail
Congress Presentation
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
3 September 2019
thumbnail
Congress Presentation
Hemodynamic pulmonary response to exercise according to different resting pulmonary hypertension thresholds in chronic thromboembolic pulmonary disease
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources